Key result
Calcium cycling defects in the phospholamban-SERCA Ca2+ pump system of the cardiac sarcoplasmic reticulum underlie the pathophysiological development of cardiac hypertrophy and failure.
This review elucidates the molecular mechanisms of phospholamban-mediated regulation of the SERCA2a calcium pump, providing foundational knowledge for understanding calcium cycling defects in cardiac hypertrophy and failure.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for heart failure; leaves open targeted calcium-cycling therapies.
he sarcoplasmic reticulum (SR) is a tubular, membranous network within muscle cells, which is the analogue of the endoplasmic reticulum (ER) in other cells. This organelle has a variety of functions, of which release of Ca 2+ to the cytosol and reuptake into the interior compartment (the lumen) of the SR are the most important. Rapid release of Ca 2+ through a Ca 2+ release channel (ryanodine receptor) in the skeletal muscle SR is responsible for muscle contraction: reuptake of Ca 2+ by the action of a Ca 2+ -ATPase is responsible for muscle relaxation. In cardiac muscle, however, the intracellular Ca 2+ concentration is controlled not only by the SR, but also by other pumps, channels, and exchangers located in the sarcolemma/T-tubules. Nonetheless, the SR of mammalian cardiac cells is well developed and has a major role in the EC coupling. In the SR of cardiac muscle, as well as in slow-twitch skeletal and smooth muscles, phospholamban (PLN) participates in the EC coupling processes by regulating the activity of the Ca 2+ -ATPase. Of particular interest is the molecular mode of PLN-mediated regulation of SR Ca 2+ -ATPase, in which cAMP-dependent protein kinase (PKA)-catalyzed phosphorylation of PLN results in marked augmentation of the Ca 2+ -ATPase activity. The molecular structure and function of the 2 important proteins in cardiac SR are highlighted in this review: Ca 2+ -ATPase and PLN and their molecular interactions, which would help understand the positive and negative inotropic effects of -adrenergic agonist/antagonist. The pathophysiological consequences of molecular perturbation of such a system are also briefly mentioned, leading to an evolving notion that 'calcium cycling defects' underlie cardiac hypertrophy and failure.
No takes yet. Share an insight, caveat, or question.
Michihiko Tada (2003) conducted a review in Cardiac hypertrophy and failure. Calcium cycling defects in the phospholamban-SERCA Ca2+ pump system of the cardiac sarcoplasmic reticulum underlie the pathophysiological development of cardiac hypertrophy and failure.
Synapse has enriched 10 related papers. Consider them for comparative context: